Pain medicine (Malden, Mass.) · 2024
Predictors of persistent opioid use in Australian primary care: a retrospective cohort study, 2018-2022.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jung Monica, Xia Ting, Ilomäki Jenni, Pearce Christopher, Aitken Angela, Nielsen Suzanne
Аннотация
OBJECTIVE: To examine the predictors of persistent opioid use ("persistence") in people initiating opioids for non-cancer pain in Australian primary care.
DESIGN: A retrospective cohort study.
SETTING: Australian primary care.
SUBJECTS: People prescribed opioid analgesics between 2018 and 2022, identified through the Population Level Analysis and Reporting (POLAR) database.
METHODS: Persistence was defined as receiving opioid prescriptions for at least 90 days with a gap of less than 60 days between subsequent prescriptions. Multivariable logistic regression was used to examine the predictors of persistent opioid use.
RESULTS: The sample consisted of 343 023 people initiating opioids for non-cancer pain; of these, 16 527 (4.8%) developed persistent opioid use. Predictors of persistence included older age (≥75 vs 15-44 years: adjusted odds ratio: 1.67, 95% CI: 1.58-1.78); concessional beneficiary status (1.78, 1.71-1.86); diagnosis of substance use disorder (1.44, 1.22-1.71) or chronic pain (2.05, 1.85-2.27); initiation of opioid therapy with buprenorphine (1.95, 1.73-2.20) or long-acting opioids (2.07, 1.90-2.25); provision of higher quantity of opioids prescribed at initiation (total oral morphine equivalents of ≥750 mg vs <100 mg: 7.75, 6.89-8.72); provision of repeat/refill opioid prescriptions at initiation (2.94, 2.77-3.12); and prescription of gabapentinoids (1.59, 1.50-1.68), benzodiazepines (1.43, 1.38-1.50), and z-drugs (eg, zopiclone, zolpidem; 1.61, 1.46-1.78).
CONCLUSIONS: These findings add to the limited evidence of individual-level factors associated with persistent opioid use. Further research is needed to understand the clinical outcomes of persistent opioid use in people with these risk factors to support the safe and effective prescribing of opioids.
DESIGN: A retrospective cohort study.
SETTING: Australian primary care.
SUBJECTS: People prescribed opioid analgesics between 2018 and 2022, identified through the Population Level Analysis and Reporting (POLAR) database.
METHODS: Persistence was defined as receiving opioid prescriptions for at least 90 days with a gap of less than 60 days between subsequent prescriptions. Multivariable logistic regression was used to examine the predictors of persistent opioid use.
RESULTS: The sample consisted of 343 023 people initiating opioids for non-cancer pain; of these, 16 527 (4.8%) developed persistent opioid use. Predictors of persistence included older age (≥75 vs 15-44 years: adjusted odds ratio: 1.67, 95% CI: 1.58-1.78); concessional beneficiary status (1.78, 1.71-1.86); diagnosis of substance use disorder (1.44, 1.22-1.71) or chronic pain (2.05, 1.85-2.27); initiation of opioid therapy with buprenorphine (1.95, 1.73-2.20) or long-acting opioids (2.07, 1.90-2.25); provision of higher quantity of opioids prescribed at initiation (total oral morphine equivalents of ≥750 mg vs <100 mg: 7.75, 6.89-8.72); provision of repeat/refill opioid prescriptions at initiation (2.94, 2.77-3.12); and prescription of gabapentinoids (1.59, 1.50-1.68), benzodiazepines (1.43, 1.38-1.50), and z-drugs (eg, zopiclone, zolpidem; 1.61, 1.46-1.78).
CONCLUSIONS: These findings add to the limited evidence of individual-level factors associated with persistent opioid use. Further research is needed to understand the clinical outcomes of persistent opioid use in people with these risk factors to support the safe and effective prescribing of opioids.